Its’ inhibitors, including tofacitinib (JAK1/3-inhibitor) and baricitinib (JAK1/2-inhibitor), block the pathway in Th17 cells, which showed promising perspectives in psoriasis treatment [59]. Here, JAK1 is linked to psoriasis.